SCHEMBL17199352

SCHEMBL17199352

Cc1cnoc1C(=O)Nc1nn(Cc2ccc(CF)cc2)c2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FSCN1 Q16658 1/20 0.52
HDAC6 Q9UBN7 3/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC3 O15379 2/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
CNR1 P21554 1/20 0.39
PTGER4 P35408 7/20 0.39
F2RL3 Q96RI0 1/20 0.38
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
CPT1A P50416 1/20 0.36
CPT1B Q92523 1/20 0.36
CYP2D6 P10635 1/20 0.36
PDE5A O76074 1/20 0.35
SLC16A3 O15427 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17038845 0.90 FSCN1 (0.66) FSCN1HDAC6HDAC1HDAC10HDAC3
SCHEMBL30501123 0.90 FSCN1 (0.66) FSCN1HDAC6HDAC1HDAC10HDAC3
SCHEMBL17199353 0.85 FSCN1 (0.57) FSCN1HDAC6HDAC1HDAC10HDAC3
SCHEMBL17199346 0.83 FSCN1 (0.58) FSCN1HDAC6HDAC1HDAC10HDAC3
SCHEMBL17199362 0.83 FSCN1 (0.56) FSCN1HDAC6HDAC1HDAC10HDAC3
SCHEMBL17199316 0.82 FSCN1 (0.54) FSCN1HDAC6HDAC1HDAC10HDAC3
SCHEMBL17199315 0.81 FSCN1 (0.55) FSCN1HDAC6HDAC1HDAC10HDAC3
SCHEMBL17199370 0.80 FSCN1 (0.51) FSCN1HDAC6HDAC1HDAC10HDAC3
SCHEMBL17199347 0.80 FSCN1 (0.60) FSCN1HDAC6HDAC1HDAC10HDAC3
SCHEMBL23986327 0.79 FSCN1 (0.55) FSCN1HDAC1PTGER4CPT1ACPT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170158692-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN CORNELL UNIVERSITY 2017-06-08 US disclosed
US-9573946-B2 Compounds and methods for inhibiting fascin NOVITA PHARMACEUTICALS, INC. (US) 2017-02-21 US disclosed
US-20150299191-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN CORNELL UNIVERSITY 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299191-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN FSCN1, MTPN, MYOF FSCN1 1/4885HDAC6 76/4885HDAC1 1006/4885
US-20170158692-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN FSCN1, MTPN, MYOF FSCN1 1/4885HDAC6 76/4885HDAC1 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.